These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16651853)

  • 1. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
    Breen EC; Fatahi S; Epeldegui M; Boscardin WJ; Detels R; Martínez-Maza O
    Tumour Biol; 2006; 27(4):187-94. PubMed ID: 16651853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
    Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
    Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.
    Widney D; Gundapp G; Said JW; van der Meijden M; Bonavida B; Demidem A; Trevisan C; Taylor J; Detels R; Martínez-Maza O
    Clin Immunol; 1999 Nov; 93(2):114-23. PubMed ID: 10527687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma.
    Yawetz S; Cumberland WG; van der Meyden M; Martínez-Maza O
    Blood; 1995 Apr; 85(7):1843-9. PubMed ID: 7703491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.
    Regidor DL; Detels R; Breen EC; Widney DP; Jacobson LP; Palella F; Rinaldo CR; Bream JH; Martínez-Maza O
    AIDS; 2011 Jan; 25(3):303-14. PubMed ID: 21192231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype.
    Breen EC; Boscardin WJ; Detels R; Jacobson LP; Smith MW; O'Brien SJ; Chmiel JS; Rinaldo CR; Lai S; Martínez-Maza O
    Clin Immunol; 2003 Nov; 109(2):119-29. PubMed ID: 14597210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
    Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
    Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD30 ligand in lymphoma patients with CD30+ tumors.
    Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
    J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
    Epeldegui M; Lee JY; Martínez AC; Widney DP; Magpantay LI; Regidor D; Mitsuyasu R; Sparano JA; Ambinder RF; Martínez-Maza O
    Clin Cancer Res; 2016 Jan; 22(2):328-36. PubMed ID: 26384320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs?
    Schlaf G; Altermann WW; Rothhoff A; Seliger B
    Histol Histopathol; 2007 Nov; 22(11):1269-79. PubMed ID: 17647199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.
    Vendrame E; Hussain SK; Breen EC; Magpantay LI; Widney DP; Jacobson LP; Variakojis D; Knowlton ER; Bream JH; Ambinder RF; Detels R; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):343-9. PubMed ID: 24220912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
    Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
    J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6.
    Breen EC; van der Meijden M; Cumberland W; Kishimoto T; Detels R; Martínez-Maza O
    Clin Immunol; 1999 Sep; 92(3):293-9. PubMed ID: 10479534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
    Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
    Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS.
    Pizzolo G; Vinante F; Morosato L; Nadali G; Chilosi M; Gandini G; Sinicco A; Raiteri R; Semenzato G; Stein H
    AIDS; 1994 Jun; 8(6):741-5. PubMed ID: 8086130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys.
    Hannig H; Buske C; Mätz-Rensing K; Hunsmann G; Hiddemann W; Bodemer W
    Int J Cancer; 1998 Aug; 77(5):734-40. PubMed ID: 9688307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
    Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
    Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.
    Schroeder JR; Saah AJ; Hoover DR; Margolick JB; Ambinder RF; Martinez-Maza O; Breen EC; Jacobson LP; Variakojis D; Rowe DT; Armenian HK
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):979-84. PubMed ID: 10566552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.